Abbott Laboratories (NYSE:ABT) Stock Holdings Increased by Sendero Wealth Management LLC

Sendero Wealth Management LLC raised its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 53.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,753 shares of the healthcare product maker's stock after buying an additional 8,930 shares during the period. Sendero Wealth Management LLC's holdings in Abbott Laboratories were worth $2,913,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Bath Savings Trust Co boosted its stake in shares of Abbott Laboratories by 3.7% during the 4th quarter. Bath Savings Trust Co now owns 166,132 shares of the healthcare product maker's stock worth $18,791,000 after acquiring an additional 5,881 shares in the last quarter. Simplify Asset Management Inc. lifted its holdings in shares of Abbott Laboratories by 67.3% during the third quarter. Simplify Asset Management Inc. now owns 14,083 shares of the healthcare product maker's stock valued at $1,606,000 after purchasing an additional 5,664 shares during the last quarter. Dundas Partners LLP boosted its position in shares of Abbott Laboratories by 2.1% in the 2nd quarter. Dundas Partners LLP now owns 330,227 shares of the healthcare product maker's stock valued at $34,313,000 after purchasing an additional 6,897 shares during the period. Pensionfund Sabic acquired a new stake in Abbott Laboratories during the 4th quarter worth about $2,828,000. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of Abbott Laboratories by 19.6% in the third quarter. Sequoia Financial Advisors LLC now owns 193,764 shares of the healthcare product maker's stock worth $22,091,000 after buying an additional 31,720 shares during the period. Institutional investors own 75.18% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on ABT. Morgan Stanley boosted their target price on shares of Abbott Laboratories from $107.00 to $117.00 and gave the company an "equal weight" rating in a research note on Thursday, October 17th. Mizuho upped their price target on shares of Abbott Laboratories from $115.00 to $130.00 and gave the stock a "neutral" rating in a research note on Thursday, October 17th. Raymond James reissued a "buy" rating and issued a $129.00 price target (up previously from $122.00) on shares of Abbott Laboratories in a research note on Monday, October 14th. Jefferies Financial Group increased their target price on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a "hold" rating in a research report on Thursday, October 17th. Finally, Royal Bank of Canada lifted their price target on shares of Abbott Laboratories from $125.00 to $130.00 and gave the company an "outperform" rating in a research report on Tuesday, October 8th. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $131.57.

Abbott Laboratories Stock Down 1.8 %

NYSE ABT opened at $110.96 on Thursday. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $121.64. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The stock has a market cap of $192.46 billion, a PE ratio of 33.73, a PEG ratio of 2.69 and a beta of 0.73. The firm has a 50-day simple moving average of $115.14 and a 200 day simple moving average of $112.67.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.01. The company had revenue of $10.64 billion for the quarter, compared to analyst estimates of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. Abbott Laboratories's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.14 EPS. On average, research analysts forecast that Abbott Laboratories will post 4.67 EPS for the current year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a yield of 2.13%. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.55. Abbott Laboratories's payout ratio is currently 71.73%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.